

Editorial & Advisory Boards

Pharmacy Practice Editorial Board

David A. Holdford (associate editor)
Virginia Commonwealth University (USA)

Shalom I. Benrimoj
University of Granada (Spain)

Karen B. Farris
University of Michigan (USA)

Martin Schulz
Freie Universitaet Berlin and ABDA – Federal Union of German Associations of Pharmacists (Germany)

Cassyano J. Correr
Federal University of Parana (Brazil)

Fernanda S. Tonin
Federal University of Parana (Brazil)

Jonathan Penn
University of Sydney (Australia)

Meagen Rosenthal
University of Mississippi (USA)

Carrie M. Blanchard
University of North Carolina (USA)

Sarah Dineen-Griffin
University of Technology Sydney (Australia)

Advisory Board

Marja Airaksinen, University of Helsinki (Finland)
Simon Bell, University of South Australia (Australia)
Maria Cordina, University of Malta (Malta)
Souheil Hallit, Holy Spirit University of Kaslik (Lebanon)
Mohamed A. Hassali, University Sains Malaysia (Malaysia)
James Hoehns, University of Iowa (USA)
Carmel Hughes, Queen's University Belfast (UK)
Ulrich Jaehde, University of Bonn (Germany)
Rosemin Kassam, University of British Columbia (Canada)
David Nau, Pharmacy Quality Solutions (USA)
Julie A. Patterson, Virginia Commonwealth University (USA)
Kimberly S. Plake, Purdue University (USA)
Bandana Saini, University of Sydney (Australia)
Anthony Serracino-Inglott, University of Malta (Malta)
Mary Tully, University of Manchester (UK)
Asim Ahmed Elnour, Al Ain University (UAE)

[Make a Submission](https://www.pharmacypractice.org/index.php/pp/about/submissions) (https://www.pharmacypractice.org/index.php/pp/about/submissions)

Browse

Categories

- » [Pharm Pract \(Granada\) editorial policy](https://www.pharmacypractice.org/index.php/pp/catalog/category/EditPolicy) (https://www.pharmacypractice.org/index.php/pp/catalog/category/EditPolicy)
- » [Simulated Patient Technique](https://www.pharmacypractice.org/index.php/pp/catalog/category/SimPatTech) (https://www.pharmacypractice.org/index.php/pp/catalog/category/SimPatTech)
- » [Integration of community pharmacy in primary health care](https://www.pharmacypractice.org/index.php/pp/catalog/category/integration) (https://www.pharmacypractice.org/index.php/pp/catalog/category/integration)
- » [Medication Adherence](https://www.pharmacypractice.org/index.php/pp/catalog/category/medadh) (https://www.pharmacypractice.org/index.php/pp/catalog/category/medadh)

ORIGINAL RESEARCH

Impact of automated drug dispensing system on patient safety (<https://www.pharmacypractice.org/index.php/pp/article/view/2744>)



(<https://www.pharmacypractice.org/index.php/pp/article/view/2744>)

Majed Falah Alanazi, Majed Ibrahim Shahein, Hamad Mohammed Alsharif, Saif Mohammed Alotaibi, Abdulsalam Owaith Alanazi, Ahmed Obaidallah Alanazi, Umar Abdolah Alharbe, Hanad S.S. Almfalh, Palanisamy Amirthalingam, Ahmed Mohsen Hamdan, Vinoth Prabhu Veeramani, Shahul Hameed Pakkir Mohamed, Mostafa A. Sayed Ali
Abstract 803 | PDF Downloads 646 | DOI <https://doi.org/10.18549/PharmPract.2022.4.2744>
(<https://doi.org/10.18549/PharmPract.2022.4.2744>)
 Page 1-11

Knowledge and attitude regarding coronavirus disease 2019 (COVID-19) among hospital pharmacists in Qatar (<https://www.pharmacypractice.org/index.php/pp/article/view/2646>)



(<https://www.pharmacypractice.org/index.php/pp/article/view/2646>)

Lama Madi, Doua Alsaad, Raja Al Khawaja, Wessam El Kassem, Moza Al Hail
Abstract 484 | PDF Downloads 458 | DOI <https://doi.org/10.18549/PharmPract.2022.4.2646>
(<https://doi.org/10.18549/PharmPract.2022.4.2646>)
 Page 01-08

Conceptualization, development, and evaluation of 'pharmaceutical product development' graduate program within pharmacy discipline (<https://www.pharmacypractice.org/index.php/pp/article/view/2662>)



(<https://www.pharmacypractice.org/index.php/pp/article/view/2662>)

Aliasgar Shahiwala, Sabeena Salam
Abstract 324 | PDF Downloads 371 | DOI <https://doi.org/10.18549/PharmPract.2022.4.2662>
(<https://doi.org/10.18549/PharmPract.2022.4.2662>)
 Page 01-07

C-reactive protein point of care testing in community pharmacy: Observational study of a Northern Ireland pilot (<https://www.pharmacypractice.org/index.php/pp/article/view/2711>)



(<https://www.pharmacypractice.org/index.php/pp/article/view/2711>)

Katherine O'Neill, Glenda Fleming, Michael SCOTT, Gillian Plant, Sumanthra Varma
Abstract 459 | PDF Downloads 404 | DOI <https://doi.org/10.18549/PharmPract.2022.4.2711>
(<https://doi.org/10.18549/PharmPract.2022.4.2711>)
 Page 1-10

Oncological patient management on the territory: The results of a survey in the north-west of Italy (<https://www.pharmacypractice.org/index.php/pp/article/view/2716>)



(<https://www.pharmacypractice.org/index.php/pp/article/view/2716>)

Francesca Baratta, Irene Pignata, Gaia Vicenzi, Lorenzo Ravetto Enri, Pietro Quaglino, Alessandro Comandone, Ada Ala, Massimiliano Icardi, Rosella Spadi, Paola Brusa
Abstract 348 | PDF Downloads 358 | DOI <https://doi.org/10.18549/PharmPract.2022.4.2716>
(<https://doi.org/10.18549/PharmPract.2022.4.2716>)
 Page 1-9

Characterisation of institutionalised Portuguese older adult fallers: is there a place for pharmacist intervention? A preliminary study (<https://www.pharmacypractice.org/index.php/pp/article/view/2799>)






(<https://www.pharmacypractice.org/index.php/pp/article/view/2799>)

Carina Ramos Ferreira, Filipa MASCARENHAS-MELO, Ana Rita Rodrigues, Maria João Reis Lima, João Páscoa Pinheiro, Claudia CHAVES, Edite Teixeira-Lemos, Victoria Bell
Abstract 380 | PDF Downloads 388 | DOI <https://doi.org/10.18549/PharmPract.2022.4.2717>
(<https://doi.org/10.18549/PharmPract.2022.4.2717>)
 Page 1-10






(<https://www.pharmacypractice.org/index.php/pp/article/view/2799>)




Assessing adherence to medications: Is there a difference between a subjective method and an objective method, or between using them concurrently? (<https://www.pharmacypractice.org/index.php/pp/article/view/2723>)

Razan I. Nassar, Bandana Saini, Nathir M. Obeidat, Noor Atatreh, Iman A. Basheti
Abstract  425 | PDF Downloads  409 | DOI <https://doi.org/10.18549/PharmPract.2022.4.2723>
(<https://doi.org/10.18549/PharmPract.2022.4.2723>)
 Page 1-7



Double blind randomized controlled trial for subjects undergoing surgery receiving surgical antimicrobial prophylaxis at tertiary hospital: the clinical pharmacist's interventions (<https://www.pharmacypractice.org/index.php/pp/article/view/2727>)

Asim Ahmed Elnour, Israa Y Al- Khidir, Habab Elkheir, Abdalla Elkhawad, Ahmed A Mohammed O, Al-Kubaissi Khalid A, Ghadah Nahar, Shahad Fayad Alrwili, Donia Ahmed Alshelaly, Amjad Saleh, Latefa khulif Aljaber, Abrar Ayad Alrashedi
Abstract  438 | PDF Downloads  392 | DOI <https://doi.org/10.18549/PharmPract.2022.4.2727>
(<https://doi.org/10.18549/PharmPract.2022.4.2727>)
 Page 1-17




Your clinical pharmacist can save your life, the impact of pharmacists intervention (<https://www.pharmacypractice.org/index.php/pp/article/view/2729>)

Éva Ságiné Polics, Zsófia Romvári, Katalin Dormán, Dóra Endrei
Abstract  465 | PDF Downloads  429 | DOI <https://doi.org/10.18549/PharmPract.2022.4.2729>
(<https://doi.org/10.18549/PharmPract.2022.4.2729>)
 Page 1-7



Evaluation of patient comprehension and quality of consumer medicine information (<https://www.pharmacypractice.org/index.php/pp/article/view/2730>)

Supawinee Pongpunna, Kamonphat Wongtaweeekij, Thongchai Pratipanawat, Narumol Jarernsiripornkul
Abstract  352 | PDF Downloads  355 | DOI <https://doi.org/10.18549/PharmPract.2022.4.2730>
(<https://doi.org/10.18549/PharmPract.2022.4.2730>)




Investigation of the boxed warnings in package inserts of prescription medicines for medical professionals in Japan (<https://www.pharmacypractice.org/index.php/pp/article/view/2733>)

Yasuaki Mino, Takafumi Naito, Junya Ohshiro, Takahiro Yamada, Junichi Kawakami
Abstract  386 | PDF Downloads  328 | DOI <https://doi.org/10.18549/PharmPract.2022.4.2733>
(<https://doi.org/10.18549/PharmPract.2022.4.2733>)
 Page 1-4

The impact of telepharmacy on hypertension management in the United Arab Emirates (<https://www.pharmacypractice.org/index.php/pp/article/view/2734>)

Osama Mohamed Ibrahim, Ahmad Z. Al Meslamani, Rana Ibrahim, Rawan Kaloush, Nadia Al Mazrouei
Abstract  406 | PDF Downloads  409 | DOI <https://doi.org/10.18549/PharmPract.2022.4.2734>
(<https://doi.org/10.18549/PharmPract.2022.4.2734>)
 Page 1-11

Prevalence and factors associated with potentially inappropriate medication and medication complexity for older adults in the emergency department of a secondary teaching hospital in Indonesia (<https://www.pharmacypractice.org/index.php/pp/article/view/2735>)

Khusnul Fitri Hamidah, Mahardian Rahmadi, Farah Meutia, Prihatma Kriswidyatomo, Firman Suryadi Rahman, Zamrotul Izzah, Bambang Subakti Zulkarnain, Leopold N. Aminde, Christopher Paul Alderman, Yulistiani, Budi Suprpti
Abstract  494 | PDF Downloads  475 | DOI <https://doi.org/10.18549/PharmPract.2022.4.2735>
(<https://doi.org/10.18549/PharmPract.2022.4.2735>)
 Page 1-11

 PDF

(<https://www.pharmacypractice.org/index.php/pp/article/view/2723>)

 PDF

(<https://www.pharmacypractice.org/index.php/pp/article/view/2727>)

 PDF

(<https://www.pharmacypractice.org/index.php/pp/article/view/2729>)

 PDF

(<https://www.pharmacypractice.org/index.php/pp/article/view/2730>)

 PDF

(<https://www.pharmacypractice.org/index.php/pp/article/view/2733>)

 PDF



(<https://www.pharmacypractice.org/index.php/pp/article/view/2734>)


 PDF

(<https://www.pharmacypractice.org/index.php/pp/article/view/2735>)

Medications adherence and associated factors among patients with stroke in the Kingdom of Saudi Arabia

(<https://www.pharmacypractice.org/index.php/pp/article/view/2736>)

Iman A. Basheti, Shahnaz M. Ayasrah, Muayyad M. Ahmad, Hana M. Abu-Snieneh, Fuad H. Abuadas
Abstract  506 | PDF Downloads  432 | DOI <https://doi.org/10.18549/PharmPract.2022.4.2736>
(<https://doi.org/10.18549/PharmPract.2022.4.2736>)

 Page 1-9




(<https://www.pharmacypractice.org/index.php/pp/article/view/>

A pseudo-customer cross-sectional study to evaluate the community pharmacist's management of migraine in pregnant women

(<https://www.pharmacypractice.org/index.php/pp/article/view/2739>)

Khalid Al Kubaisi, Sanah Hasan, Nageeb AbdulGalil Hassan, Asim Ahmed elnour
Abstract  363 | PDF Downloads  349 | DOI <https://doi.org/10.18549/PharmPract.2022.4.2739>
(<https://doi.org/10.18549/PharmPract.2022.4.2739>)



 Page 1-9




(<https://www.pharmacypractice.org/index.php/pp/article/view/>

Assessment of knowledge and counseling practice of warfarin among pharmacists in UAE: A cross-sectional study

(<https://www.pharmacypractice.org/index.php/pp/article/view/2741>)

Ayah Moath Alkherat, Doaa Kamal Alkhalidi
Abstract  417 | PDF Downloads  382 | DOI <https://doi.org/10.18549/PharmPract.2022.4.2741>
(<https://doi.org/10.18549/PharmPract.2022.4.2741>)



 Page 1-7



(<https://www.pharmacypractice.org/index.php/pp/article/view/>

Computational medicinal chemistry role in clinical pharmacy education: Ingavirin for coronavirus disease 2019 (COVID-19) discovery model

(<https://www.pharmacypractice.org/index.php/pp/article/view/2746>)

Loai M Saadah, Ghina'a I Abu Deiab, Qosay Al-Balas, Iman A Basheti
Abstract  424 | PDF Downloads  375 | DOI <https://doi.org/10.18549/PharmPract.2022.4.2746>
(<https://doi.org/10.18549/PharmPract.2022.4.2746>)



 Page 1-7




(<https://www.pharmacypractice.org/index.php/pp/article/view/>

Promoting rational herb-drug use through pharmacy-led advice and home visits in NCD patients

(<https://www.pharmacypractice.org/index.php/pp/article/view/2747>)

Chanuttha Ploylearmsang, Juntip Kanjanasilp, Juthamas Tadtianant, Piyaporn Sisala
Abstract  329 | PDF Downloads  358 | DOI <https://doi.org/10.18549/PharmPract.2022.4.2747>
(<https://doi.org/10.18549/PharmPract.2022.4.2747>)



 Page 1-10




(<https://www.pharmacypractice.org/index.php/pp/article/view/>

Supporting and inhibiting factors of accepting COVID-19 booster vaccination in the elderly in north Jakarta, Indonesia

(<https://www.pharmacypractice.org/index.php/pp/article/view/2748>)

Fonny Cokro, Sharon, Hadiyanto
Abstract  453 | PDF Downloads  427 | DOI <https://doi.org/10.18549/PharmPract.2022.4.2748>
(<https://doi.org/10.18549/PharmPract.2022.4.2748>)



 Page 1-9




(<https://www.pharmacypractice.org/index.php/pp/article/view/>

A questionnaire based survey among pharmacy practitioners to evaluate the level of knowledge and confidence towards antimicrobial stewardship

(<https://www.pharmacypractice.org/index.php/pp/article/view/2757>)

Syed Wasif Gillani, Manar Khalil Saeed Shahwan, Doreen E. Szollosi
Abstract  457 | PDF Downloads  402 | DOI <https://doi.org/10.18549/PharmPract.2022.4.2757>
(<https://doi.org/10.18549/PharmPract.2022.4.2757>)

 Page 1-9

Categories

- » [Pharm Pract \(Granada\) editorial policy](https://www.pharmacypractice.org/index.php/pp/catalog/category/EditPolicy) (https://www.pharmacypractice.org/index.php/pp/catalog/category/EditPolicy)
- » [Simulated Patient Technique](https://www.pharmacypractice.org/index.php/pp/catalog/category/SimPatTech) (https://www.pharmacypractice.org/index.php/pp/catalog/category/SimPatTech)
- » [Integration of community pharmacy in primary health care](https://www.pharmacypractice.org/index.php/pp/catalog/category/integration) (https://www.pharmacypractice.org/index.php/pp/catalog/category/integration)
- » [Medication Adherence](https://www.pharmacypractice.org/index.php/pp/catalog/category/medadh) (https://www.pharmacypractice.org/index.php/pp/catalog/category/medadh)

Pharmacy Practice | e-ISSN: **1886-3655** - p-ISSN: **1885-642X** - CODEN: **PPHRGO**
(<https://www.pharmacypractice.org/journal/index.php/pp/authors#a4>)

[Privacy Policy](#)

eISSN: 1886-3655 (Electronic)
ISSN: 1885-642X (Print)

OJS Hosting, Support, and Customization by: [OpenJournalSystems.com](https://openjournalsystems.com) (https://openjournalsystems.com/ojs-hosting)

Original Research

Prevalence and factors associated with potentially inappropriate medication and medication complexity for older adults in the emergency department of a secondary teaching hospital in Indonesia

Khusnul Fitri Hamidah , Mahardian Rahmadi , Farah Meutia , Prihatma Kriswidyatomo , Firman Suryadi Rahman , Zamrotul Izzah , Bambang Subakti Zulkarnain , Leopold N. Aminde , Christopher Paul Alderman , Yulistiani , Budi Suprapti 

Received (first version): 01-Sep-2022

Accepted: 19-Sep-2022

Published online: 08-Nov-2022

Abstract

Background: Older adults experience progressive decline in various organs and changes in pharmacokinetics and pharmacodynamics of the drugs in the body which lead to an increased risk of medication-related problems. Potentially inappropriate medications (PIMs) and medication complexity are key factors contributing to adverse drug events in the emergency department (ED). **Objective:** To estimate the prevalence and investigate the risk factors of PIMs and medication complexity among older adults admitted to the ED. **Methods:** A retrospective observational study was conducted among patients aged > 60 years admitted to the ED of Universitas Airlangga Teaching Hospital in January - June 2020. PIMs and medication complexity were measured using the 2019 American Geriatrics Society Beers Criteria® and Medication Regimen Complexity Index (MRCI), respectively. **Results:** A total of 1005 patients were included and 55.0% (95% confidence interval [CI]: 52 – 58%) of them received at least one PIM. Whereas, the pharmacological therapy prescribed to older adults had a high complexity index (mean MRCI 17.23 + 11.15). Multivariate analysis showed that those with polypharmacy (OR= 6.954; 95% CI: 4.617 – 10.476), diseases of the circulatory system (OR= 2.126; 95% CI: 1.166 – 3.876), endocrine, nutritional, and metabolic diseases (OR= 1.924; 95% CI: 1.087 – 3.405), and diseases of the digestive system (OR= 1.858; 95% CI: 1.214 – 2.842) had an increased risk of receiving PIM prescriptions. Meanwhile, disease of the respiratory system (OR = 7.621; 95% CI: 2.833 – 15.150), endocrine, nutritional and metabolic diseases (OR = 6.601; 95% CI: 2.935 – 14.847), and polypharmacy (OR = 4.373; 95% CI: 3.540 – 5.401) were associated with higher medication complexity. **Conclusion:** In our study, over one in every two older adults admitted to the ED had PIMs, and a high medication complexity was observed. Endocrine, nutritional and metabolic disease was the leading risk factors for receiving PIMs and high medication complexity.

Keywords: beers criteria; elderly; medication regimen complexity index; medication-related problem; polypharmacy

Khusnul Fitri HAMIDAH. Department of Pharmacy, Universitas Airlangga Teaching Hospital, Surabaya, Indonesia. khusnul.fitri.hamidah-2018@ff.unair.ac.id
Mahardian RAHMADI*. Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia. mahardianr@ff.unair.ac.id
Farah MEUTIA. Master of Clinical Pharmacy Program, Faculty of Pharmacy, Universitas Airlangga Surabaya, Indonesia. farah.meutia-2020@ff.unair.ac.id
Prihatma KRISWIDYATOMO. Department of Anesthesiology and Reanimation, Faculty of Medicine, Universitas Airlangga, Emergency Department, Universitas Airlangga Teaching Hospital, Surabaya, Indonesia. prihatma.kriswidyatomo@staf.unair.ac.id
Firman Suryadi RAHMAN. Doctoral Program of Public Health, Faculty of Public Health, Universitas Airlangga, Surabaya, Indonesia. firman.suryadi.rahman-2018@fkm.unair.ac.id
Zamrotul IZZAH. Department of Pharmacy, Universitas Airlangga Teaching Hospital, Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia. Groningen Research Institute of

Pharmacy, University of Groningen, Groningen, The Netherlands. zamrotulizzah@ff.unair.ac.id
Bambang Subakti ZULKARNAIN. Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia. bambang-s-z@ff.unair.ac.id
Leopold N. AMINDE. School of Medicine, Griffith University, Gold Coast, QLD, Australia. l.aminde@griffith.edu.au
Christopher Paul ALDERMAN. Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia. School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia. Chris.Alderman@unisa.edu.au
Yulistiani. Department of Pharmacy, Universitas Airlangga Teaching Hospital, Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia. yulistiani@ff.unair.ac.id
Budi SUPRAPTI. Department of Pharmacy, Universitas Airlangga Teaching Hospital, Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia. budi-s@ff.unair.ac.id



INTRODUCTION

Potentially inappropriate medication (PIM) is one of the factors causing medication-related problems in older adults.¹⁻³ PIM is a drug with a risk of adverse effects more significant than its benefits when used by older adults, especially if safer alternative therapies are available and provide the same effectiveness.⁴ PIM prescriptions in older adults are a recognized problem for health services, contributing to the increased prevalence of morbidity, hospitalization, and costs.¹

The most frequently used approach to identify the presence of PIM in patients' therapy is the American Geriatrics Society (AGS) Beers Criteria[®], an interdisciplinary consensus-based approach that lists drugs categorized as PIM in older adults. The Beers Criteria[®] is continuously updated and an important measurement tool in identifying PIM to improve the quality and safety of the therapy. Moreover, the Beers Criteria[®] can be used in various service areas.^{2,5,6}

Older adults experience a progressive decline in various systems and organs. These contribute to increase the prevalence of disease and susceptibility to receive more medications. They receive more than two types of drugs and polypharmacy occurs in 20-50% of these elderly patients.^{5,7} As a consequence, it may put them at high risk of drug-related problems and lead to hospital admission.

Globally, the number of older patients admitted to hospital emergency departments (ED) increase significantly annually, which is in line with the growth in ageing populations and increasing life expectancy.⁸ In 2015, about 13 million patients came to the ED with a history of diabetes in America, 59% of them were older adults.⁹ In Indonesia, almost 25% of people aged > 65 years visit the ED at least once a year, and 8% undergo repeat visits.¹⁰ On the other hand, the ED is a high-risk service area for the occurrence of medication errors in the hospital. Some contributing factors include: (1) patients in emergency conditions; (2) patients of various ages; (3) high use of high alert drugs; (4) treatment is carried out simultaneously on patients; (5) and the lack of ability of health workers to communicate with patients due to the density of services.¹¹

In 2003–2012, the prevalence of PIM in older adults identified by the Beers Criteria[®] increased from 5.6% to 26% in European and Asian countries.¹² Even though older patients get medications in a single dose and for a short time in the ED, some drugs can cause serious side effects. Another study in the United States showed that at least 7% of patients presenting with myocardial infarction required dose adjustment because of actual side effects. In older patients who require more therapy, it is necessary to consider the risk of PIM use and drug interactions¹¹⁻¹³.

Besides PIM, medication regimen complexity also plays a role in drug-related problems and the incidence of readmissions and hospitalizations in elderly patients. Therefore, hospital pharmacists should pay attention to the medication complexity in older patients. The medication regimen complexity index (MRCI) is a validated instrument that can be used to describe

the complexity of medications, including drug dosage forms, dosing frequency, and additional directions.^{5,14,15}

To the best of the authors knowledge, there is limited information regarding PIM and medication complexity among the Indonesian population. Previous studies were performed using the 2015 Beers Criteria[®] and no recent study in Indonesia has been conducted with the updated 2019 version.^{1,16-18} Therefore, to complement this knowledge gap, studies on PIM and medication complexity in older adults visiting the hospital ED in Indonesia are needed to improve patient safety. Moreover, the study results can be utilized to identify older patients at risk of adverse drug events or who require supervision from specialist medical personnels.¹⁴

METHODS

Study design and setting

A retrospective observational study was conducted at the ED of Universitas Airlangga (UNAIR) Teaching Hospital in Indonesia, located in Surabaya, East Java Province, which receives 80-120 emergency patients daily. A clinical pharmacist together with a hospital pharmacist and seven pharmacy technicians provide pharmacy services in the ED, such as reviewing prescribed medicines, drug reconciliation, working collaboratively with physicians and nurses to control patients with intoxication.¹⁹

Data were extracted from patient medical records admitted to the ED during January to June 2020 (Figure 1). The study protocol was approved by the Ethics committee of UNAIR Teaching Hospital (Approval certificate no.177/KEP/2020) prior to the commencement of the study.




Figure 1. Study enrolment flowchart

Data collection

Data were recorded on the data collection sheet and kept confidential during collection. Data collection included demographic (gender, year of birth or age, occupation), clinical characteristics (triage level, underlying diseases or diagnosis, comorbidities), laboratory and supporting examinations (serum



electrolytes, creatinine, blood glucose, full blood count), and prescribed medications (active substance, strength, dosage form, route of administration, dosing frequency, and additional instructions, if applicable).

Diseases classification and comorbidity

A classification of diseases was carried out using the International Classification of Diseases and Related Health Problems, tenth revision (ICD-10).²⁰ In addition, the comorbidity index was calculated using the validated Charlson Comorbidity Index (CCI).¹⁶ The prevalence of each disease group and comorbid index were further calculated.

Potentially inappropriate medications assessment

The primary outcome of this study was the prevalence and risk factors for PIMs in older adult patients in the ED. PIMs were analyzed based on the 2019 AGS Beers Criteria[®]. We summarised the PIM assessment in our study population in a tabular format according the type and number of PIMs in each category.

Medication regimen complexity assessment

As the secondary outcome, the medication regimen complexity was measured using the validated MRCI,¹⁴ which includes 65 assessment items categorized. The complexity index was assessed for each therapy received by older adult patients based on predetermined parameters and values, namely: (1) dosage forms; (2) dosing frequency; and (3) additional directions.¹³ Then, the values obtained in each subgroup were summed, tabled and classified to get the mean of MRCI as a cut-off point for high complexity category. A higher MRCI score indicates higher complexity.

Statistical analysis

Descriptive analysis was done by summarising the categorical variables as counts with percentages and continuous variables as means with standard deviation. Continuous variables checked using the Kolmogorov-Smirnov test. The prevalence of PIM was estimated by dividing the number of older patients by the total study population. We conducted univariate binary logistic regression analyses to investigate factors associated with PIM use and MRCI. The following factors were tested: diseases groups by ICD-10 classification, comorbidities, and the number of prescribed medications. To determine factors that were independently associated with PIM use and high medication complexity, all factors that were statistically significant in the univariate analyses were used to build a multivariate logistic regression model. All statistical analyses were carried out in the Statistical Package for the Social Sciences (SPSS) version 25 with a significance level of $\alpha = 0.05$.

RESULTS

General characteristics

In this study, a total of 1005 emergency visits of patients aged ≥ 60 years with a yellow or red triage and received at least one

therapy were included. The mean age was 69.2 ± 7.2 years and 50.7% were female. More than half (59.1%) of the participants had comorbidities and nearly one-third (29.2%) of visits had polypharmacy. Demographic and clinical characteristics of study population can be seen in Table 1.

| Variable | n (%) |
|---|------------|
| No. of visits | 1005 |
| Gender | |
| Male | 495 (49.3) |
| Female | 510 (50.7) |
| Age (years) | |
| 60 – 64 | 314 (31.2) |
| 65 – 69 | 283 (28.2) |
| 70 – 74 | 189 (18.8) |
| ≥ 75 | 219 (21.8) |
| ED triage | |
| Yellow | 746 (74.2) |
| Red | 259 (25.8) |
| Charlson Comorbidity Index | |
| No comorbidity (0) | 411 (40.9) |
| Mild (1 – 2) | 559 (55.6) |
| Moderate (3 – 4) | 32 (3.2) |
| Severe (≥ 5) | 3 (0.3) |
| Disease groups (ICD-10) | |
| Diseases of the respiratory system | 194 (19.3) |
| Diseases of the digestive system | 177 (17.6) |
| Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | 155 (15.4) |
| Diseases of the circulatory system | 107 (10.6) |
| Diseases of the nervous system | 94 (9.4) |
| Endocrine, nutritional and metabolic diseases | 94 (9.4) |
| Diseases of the genitourinary system | 61 (6.1) |
| Injury, poisoning and certain other consequences of external causes | 37 (3.7) |
| Certain infectious and parasitic diseases | 32 (3.2) |
| Diseases of musculoskeletal system and connective tissue | 23 (2.3) |
| Diseases of the skin and subcutaneous tissue | 13 (1.3) |
| Neoplasms | 10 (1.0) |
| Diseases of the blood and blood-forming organs | 5 (0.5) |
| Disorders of gallbladder, biliary tract and pancreas | 3 (0.3) |
| Number of prescribed medications | |
| < 5 | 712 (70.8) |
| ≥ 5 (polypharmacy) | 293 (29.2) |
| Condition after ED visit | |
| Hospitalization | 652 (64.9) |
| Discharge | 353 (35.1) |

Potentially inappropriate medications

Based on visit cases, at least one PIM was prescribed in more than half patients (55.0%, 95% confidence interval [CI]: 52 – 58%) and 62.3% of those were potentially inappropriate use in most older adults PIM criteria. The prevalence and classification of PIM are shown in Table 2. The list of top ten drugs categorized as PIM received by elderly patients in the ED is shown in Table 3. Metoclopramide was the most prescribed PIM (16.6%), followed by omeprazole (10.4%).



| | n (%) |
|---|-------------------|
| Number of PIM | |
| Visit without PIM | 452 (45.0) |
| Visit with PIM | 553 (55.0) |
| 1 | 359 (35.7) |
| 2 | 141 (14.0) |
| 3 | 40 (4.0) |
| 4 | 10 (1.0) |
| 5 | 2 (0.2) |
| 6 | 1 (0.1) |
| PIM Criteria | |
| PIM use in older adults | 512 (62.3) |
| PIM use in older adults due to drug-disease or drug-syndrome interactions that may exacerbate the disease or syndrome | 48 (5.8) |
| PIM to be used with caution | 192 (23.4) |
| PIM that should be avoided due to drug interactions | 18 (2.2) |
| PIM that should be avoided or require dose adjustment due to decreased renal function | 52 (6.3) |
| Therapeutic category | |
| Gastrointestinal medications | 352 (43.1) |
| Diuretics | 123 (15.1) |
| Nonsteroidal anti-inflammatory drugs | 103 (12.6) |
| Endocrine medications | 92 (11.3) |
| Antiplatelet aggregation | 74 (9.1) |
| Benzodiazepines | 20 (2.40) |
| Antispasmodic | 17 (2.1) |
| Cardiovascular medications | 15 (1.8) |
| Corticosteroid | 7 (0.9) |
| Anticoagulant | 3 (0.4) |
| Antihistamine | 2 (0.2) |
| Narcotic analgesics | 1 (0.1) |
| Antidepressants | 1 (0.1) |
| Central nervous system and analgesics drugs | 1 (0.1) |
| AGS American Geriatric Society, PIM potentially inappropriate medication | |

Factors associated with PIM use

From the univariate analysis, we found that having diseases of the respiratory system, digestive system, presence of symptoms, signs and abnormal clinical and laboratory findings, circulatory system, endocrine, nutritional and metabolic diseases, genitourinary system, presence of neoplasms and patients with polypharmacy had p-values < 0.25 and were considered candidate variables for inclusion in the multivariable model.

Our multivariate analysis showed that those with circulatory system diseases (OR = 2.126; 95% CI: 1.166–3.876), endocrine, nutritional and metabolic diseases (OR = 1.924; 95% CI: 1.087–3.405), and digestive system diseases (OR = 1.858; 95% CI: 1.214 – 2.842) had increased likelihood of being prescribed PIMs compared to their counterparts, while those with diseases

| Drugs listed as PIM | n (%) | Criteria for inappropriate use |
|--|------------|--|
| Metoclopramide | 167 (16.6) | It may cause extrapyramidal effects, including tardive dyskinesia; the risk may be greater in frail elderly and prolonged exposure |
| Omeprazole | 105 (10.4) | Risk of infection <i>Clostridium difficile</i> , bone loss, and fractures |
| Furosemide | 83 (8.3) | It may exacerbate or cause SIADH or hyponatremia |
| Rapid/short acting insulin | 80 (8.1) | Higher risk of hypoglycaemia; avoid insulin regimens containing only short or rapid-acting insulin and dosed according to current blood glucose levels without co-administration of basal or long-acting insulin |
| Acetylsalicylic acid | 78 (7.7) | The risk of acute bleeding from ASA increases markedly in the elderly |
| Ketorolac | 55 (5.5) | It increases the risk of gastrointestinal bleeding/peptic ulcer disease and acute kidney disease in the elderly |
| Ranitidine | 49 (4.9) | Potential to cause changes in mental status in elderly patients with creatinine clearance < 50 mL/min |
| Metamizole | 46 (4.6) | Potential to increase fluid retention and worsen heart failure |
| Spirolactone | 39 (3.9) | May worsen or cause SIADH or hyponatremia, potentially cause increased potassium levels in elderly patients with creatinine clearance < 30 mL/min. |
| Lansoprazole | 26 (2.6) | Risk of infection <i>Clostridium difficile</i> , bone loss, and fractures |
| AGS American Geriatric Society, ASA acetylsalicylic acid, PIM potentially inappropriate medication, SIADH syndrome of inappropriate antidiuretic hormone | | |

of the respiratory system (OR = 0.183; 95% CI: 0.112–0.302), symptoms, signs, and abnormal clinical and laboratory findings (OR = 0.668; 95% CI: 0.430 – 1.036) had lower odds of being prescribed PIMs compared to their counterparts who did not have these conditions. Table 4 depicts our regression results for factors associated with the use of PIMs in elderly patients in the ED.

Medication regimen complexity

The mean of MRCI scores was 17.23 ± 11.15 with cut-off upper quartile, thus the scores were categorized into two groups: high complexity with MRCI score ≥ 24 and low with MRCI score < 24. Our multivariate analysis showed that those with respiratory system disease (OR = 7.621; 95% CI: 2.833–5.150), and endocrine, nutritional and metabolic diseases (OR = 6.601; 95% CI: 2.935–14.847) were highly correlated with MRCI scores, while those with musculoskeletal system and connective tissue disease (OR = 1.974; 95% CI: 0.175 – 22.209), nervous system disease (OR = 1.746; 95% CI: 0.530 – 5.746), and symptoms,



| Table 4. Factors associated with potentially inappropriate medications use among elderly patient visits in the ED of Universitas Airlangga Teaching Hospital, Indonesia, 2020 | | | | | | |
|---|------------------|-------------|------------------------|---------|--------------------------|---------|
| Variable | PIM prescription | | Univariate analysis** | | Multivariate analysis*** | |
| | Yes n (%) | No n (%) | Odds ratio (95% CI) | p-value | Odds ratio (95% CI) | p-value |
| Disease group* | | | | | | |
| Diseases of the respiratory system | | | | | | |
| Yes | 61 (11.0) | 133 (29.4) | 0.297 | 0.000 | 0.183 | 0.000 |
| No | 492 (89.0) | 319 (70.6) | (0.213 – 0.415) | | (0.112 – 0.302) | |
| Diseases of the digestive system | | | | | | |
| Yes | 115 (20.8) | 62 (13.7) | 1.652 | 0.004 | 1.858 | 0.004 |
| No | 438 (79.2) | 390 (86.3) | (1.178 – 2.315) | | (1.214 – 2.842) | |
| Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | | | | | | |
| Yes | 63 (11.4) | 92 (20.4) | 0.503 | 0.000 | 0.668 | 0.071 |
| No | 490 (88.6) | 360 (79.6) | (0.355 – 0.713) | | (0.430 – 1.036) | |
| Diseases of the circulatory system | | | | | | |
| Yes | 87 (15.7) | 20 (4.4) | 4.033 | 0.000 | 2.126 | 0.014 |
| No | 466 (84.3) | 432 (95.6) | (2.438 – 6.671) | | (1.166 – 3.876) | |
| Diseases of the nervous system | | | | | | |
| Yes | 49 (8.9) | 45 (10.0) | 0.879 | 0.553 | - | - |
| No | 504 (91.1) | 407 (90.0) | (0.575 – 1.345) | | | |
| Endocrine, nutritional and metabolic diseases | | | | | | |
| Yes | 70 (12.7) | 24 (5.3) | 2.585 | 0.000 | 1.924 | 0.025 |
| No | 483 (87.3) | 428 (94.7) | (1.597 – 4.183) | | (1.087 – 3.405) | |
| Diseases of the genitourinary system | | | | | | |
| Yes | 42 (7.6) | 19 (4.2) | 1.873 | 0.027 | 1.669 | 0.117 |
| No | 511 (92.4) | 433 (95.8) | (1.073 – 3.269) | | (0.879 – 3.166) | |
| Injury, poisoning and certain other consequences of external causes | | | | | | |
| Yes | 17 (3.1) | 20 (4.4) | 0.685 | 0.261 | - | - |
| No | 536 (96.9) | 432 (95.6) | (0.354 – 1.324) | | | |
| Certain infectious and parasitic diseases | | | | | | |
| Yes | 16 (2.9) | 16 (3.5) | 0.812 | 0.562 | - | - |
| No | 537 (97.1) | 436 (96.5) | (0.401 – 1.642) | | | |
| Diseases of musculoskeletal system and connective tissue | | | | | | |
| Yes | 14 (2.5) | 9 (2.0) | 1.278 | 0.700 | - | - |
| No | 539 (97.5) | 443 (98.0) | (0.548 – 2.982) | | | |
| Diseases of the skin and subcutaneous tissue | | | | | | |
| Yes | 6 (1.1) | 7 (1.5) | 0.697 | 0.520 | - | - |
| No | 547 (98.9) | 445 (98.5) | (0.233 – 2.090) | | | |
| Neoplasms | | | | | | |
| Yes | 8 (1.4) | 2 (0.4) | 3.303 | 0.132 | 3.327 | 0.147 |
| No | 545 (98.6) | 450 (99.6) | (0.698 – 15.631) | | (0.656 – 16.878) | |
| Diseases of the blood and blood-forming organs | | | | | | |
| Yes | 3 (0.5) | 2 (0.4) | 1.227 | 0.823 | - | - |
| No | 550 (99.5) | 450 (99.6) | (0.204 – 7.377) | | | |
| Disorders of gallbladder, biliary tract and pancreas | | | | | | |
| Yes | 2 (0.4) | 1 (0.2) | 1.637 | 0.668 | - | - |
| No | 551 (99.6) | 451 (99.8) | (0.148 – 18.112) | | | |
| Charlson Comorbidity Index | | | | | | |
| No comorbidity (0) | 209 (37.8) | 202 (44.7) | - | - | - | - |
| Mild (1 – 2) | 320 (57.9) | 239 (52.9) | 0.517 | 0.592 | - | - |
| | | | (0.047 – 5.750) | | | |
| Moderate (3 – 4) | 22 (4.0) | 10 (2.2) | 0.669 | 0.744 | - | - |
| | | | (0.060 – 7.426) | | | |
| Severe (≥ 5) | 2 (0.4) | 1 (0.2) | 1.100 | 0.941 | - | - |
| | | | (0.089 – 13.592) | | | |

Table 4. Factors associated with potentially inappropriate medications use among elderly patient visits in the ED of Universitas Airlangga Teaching Hospital, Indonesia, 2020

| Variable | PIM prescription | | Univariate analysis** | | Multivariate analysis*** | |
|---|------------------|------------|-----------------------|---------|--------------------------|---------|
| | Yes n (%) | No n (%) | Odds ratio (95% CI) | p-value | Odds ratio (95% CI) | p-value |
| Number of prescribed medications | | | | | | |
| <5 | 325 (58.8) | 387 (85.6) | - | - | - | - |
| ≥ 5 (polypharmacy) | 228 (41.2) | 65 (14.4) | 4.177 (3.056 – 5.709) | 0.000 | 6.954 (4.617 – 10.476) | 0.000 |
| *Disease groups according to the ICD-10 | | | | | | |
| **p-value < 0,05; 95% CI (univariate analysis) | | | | | | |
| ***p-value < 0,25; 95% CI (multivariate analysis candidate) | | | | | | |

signs and abnormal clinical findings (OR = 1.502; 95% CI: 0.588 – 3.836) were not associated with MRCI score. Table 5 depicts our regression results for factors associated with high complexity use among elderly patients in the ED.

DISCUSSION

PIM is one of the most common drug-related problems encountered in older adults and negatively impacts patients' health and quality of life and also susceptible to medication complexity, contributing to adverse drug effects and elevated risk of unplanned hospitalization.^{15,21-23} This study revealed that over half of the elderly patients in the ED of UNAIR Teaching Hospital received PIMs. Over a third of them received at least one PIM and about two-thirds of PIM use was within the 'PIM use in older adults' category of the 2019 AGS Beers Criteria[®]. Our results are consistent with research conducted by Sharma et al. on the prevalence of PIM in 323 elderly patients at Guru Gobind Singh Medical College and Hospital, Punjab using the 2019 Beers Criteria[®], which demonstrated that 61.9% of prescriptions were PIMs.²⁴ Previous studies have estimated the prevalence of PIMs using the 2015 Beers Criteria[®] albeit in varied health care settings and found similar results to ours, such as in Jordan (49.2% to 62.5% among older patients),^{25,26} Saudi Arabia (61% geriatrics),²⁷ and comparatively lower prevalence was found Japan (47.9% elderly patients),²⁸ and Pennsylvania (35.8% elderly patients).²⁹ Recent studies using the 2019 Beers Criteria[®] conducted in the United Arab Emirates found that 34.7% and in China, about 74.1% of elderly patients had at least one PIM, which is more than double the finding in our study.^{30,31}

This study showed that the most common group of diseases among older adults in the ED was digestive system disorders. In addition, the most widely used PIMs came from the gastrointestinal therapeutic class (43.1%), diuretics (15.1%), and nonsteroidal anti-inflammatory drugs (12.6%). This finding is in line with a study conducted in Qatar, which showed that the most commonly used PIMs were drugs listed in gastrointestinal (84.2%) and analgesics (49.9%).³² Although PIMs prescriptions generally occur in chronic therapy, our

study showed that PIMs could also happen in acute therapy. We found that gastrointestinal drugs (i.e., metoclopramide and omeprazole) were the most common PIM. Metoclopramide was reported to reach 25% extrapyramidal effects.³³ Another study conducted in Brazil reported that 41% of elderly patients received metoclopramide.³⁴ Jeon et al. also showed that in 79,552 elderly patients in South Korea, metoclopramide was one of the most frequently used PIMs (22%).³⁵ On the other hand, omeprazole poses a risk of *Clostridium difficile* infection especially in long-term use.^{4,36} A study in Brazil showed that about a third of the elderly patients received for omeprazole. They further reported that 63% of the omeprazole prescriptions were not indicated.³⁴ Omeprazole, a proton pump inhibitor (PPI) is used for treating gastric acid disorders.³⁷

Some patient-related factors make older adults more susceptible to receiving PIMs in the ED. Our multivariate analyses showed that patients with circulatory system disorders had the highest probability, that is, compared to their counterparts, were two times as likely to get PIMs. Although diseases of the circulatory system were not the most common disease group, the therapeutic profile of cardiovascular patients put them at high risk of receiving PIM in the ED. In Pakistan, a prior study showed that nearly three-quarters of elderly patients with cardiovascular diseases had at least one PIM.³⁸ Furthermore, a European study using the START/STOPP screening criteria found similar results, where 61.5% of elderly patients with cardiovascular disorders received PIM.³⁹ Sheikh-Taha and Dimassi also reported that 87.4% of elderly patients visiting the USA cardiology unit received at least one PIM.⁴⁰ These findings suggest a need for close monitoring and caution in treating patients with cardiovascular disorders.

This research also pointed out that number of medications received by older adults had a significant effect on the prevalence of PIMs in the ED ($p < 0.005$). Elderly patients who received polypharmacy had a risk of experiencing PIM by 6.954 times than older adults who received fewer medications. Alhawassi et al. signified that elderly patients who received polypharmacy were 7.79 times more likely to receive PIM.⁴¹ Other studies conducted in Turkey and Sweden also stated that there was a significant effect of polypharmacy on the number



of PIM ($p < 0.001$).^{42,43}

Aside from potentially inappropriate prescribing, medication complexity also plays a role in drug-related problems. Research conducted by Wimmer et al. supported this finding that comorbidities lead the patients to be treated with more complex medication.¹⁵ In terms of disease groups, elderly patients have a reasonably varied MRCI score. For example, patients' endocrine diseases are more likely to receive additional directions for diabetes management. These likely contribute to increasing the prevalence of complex therapy, as observed in our study. This finding is supported by a prior study which stated that 60% of patients with diabetes mellitus received medications with high complexity (MRCI >16.5).⁴⁴

Regarding the number of medications, 77.1% of older adults received polypharmacy with high medication complexity (MRCI ≥ 24). This finding follows the results of the study of Ferreira et al., where 74.2% of patients who received polypharmacy had high MRCI values (MRCI > 13.0). Another study also showed that 37.5% of elderly patients with polypharmacy had at least

an MRCI > 16.5.⁴⁴ Moreover, dosage form, dosing frequency, and specific drug instructions also contribute to the MRCI value. In this study, the dosage form contributed to the highest average complexity value compared to dosing frequency and additional directions for drug use. Pantuzza et al. reported that among the three components of the medication regimen complexity assessment in two primary healthcare units, the dosing frequency contributed the highest average complexity value with an average MRCI lower than the results of our study. The findings from our study differ from previous studies in part because of differences in the study setting. Most of the medicines prescribed in the ED were for parenteral use, which requires sufficient knowledge (route and time of administration) to avoid medication administration errors. As a result, we found that the dosage form had the highest MRCI values.⁴⁵

Furthermore, our study showed disease of respiratory system and endocrine, nutritional and metabolic diseases had a strong association with MRCI value in the disease group, while the rest were very weak associated (Table 5).

Table 5. Factors associated with high complexity use among elderly patient visits in the ED of Universitas Airlangga Teaching Hospital, Indonesia, 2020

| Variable | MRCI mean \pm SD | MRCI | | Univariate analysis | | Multivariate analysis | |
|---|-----------------------|--------------------|-----------------------------|------------------------|---------|------------------------|---------|
| | | Low (<24) n (%) | High (≥ 24) n (%) | Odds ratio (95% CI) | p-value | Odds ratio (95% CI) | p-value |
| | | | | | | | |
| MRCI assessment | | | | | | | |
| Dosage forms | 10.95 \pm 6.401 | | | | | | |
| Dosing frequency | 5.51 \pm 4.980 | | | | | | |
| Additional instructions | 0.78 \pm 1.440 | | | | | | |
| Disease group | | | | | | | |
| Diseases of the respiratory system | | | | | | | |
| Yes | | 99 (13.3) | 95 (36.8) | 3.815 | 0.000 | 7.621 | 0.000 |
| No | | 648 (86.7) | 163 (63.2) | (2.743 – 5.305) | | (3.833 – 15.150) | |
| Diseases of the digestive system | | | | | | | |
| Yes | | 154 (20.6) | 23 (8.9) | 0.377 | 0.000 | 2.911 | 0.009 |
| No | | 593 (79.4) | 235 (91.1) | (0.237 – 0.599) | | (1.312 – 6.459) | |
| Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | | | | | | | |
| Yes | | 142 (19.0) | 13 (5.0) | 0.226 | 0.000 | 1.502 | 0.395 |
| No | | 605 (81.0) | 245 (95.0) | (0.126 – 0.407) | | (0.588 – 3.836) | |
| Diseases of the circulatory system | | | | | | | |
| Yes | | 78 (10.4) | 29 (11.2) | 1.086 | 0.720 | - | - |
| No | | 669 (89.6) | 229 (88.8) | (0.691 – 1.707) | | - | |
| Diseases of the nervous system | | | | | | | |
| Yes | | 85 (11.4) | 9 (3.5) | 0.282 | 0.000 | 1.746 | 0.359 |
| No | | 662 (88.6) | 249 (96.5) | (0.139 – 0.568) | | 0.530 – 5.746 | |
| Endocrine, nutritional and metabolic diseases | | | | | | | |
| Yes | | 52 (7.0) | 42 (16.3) | 2.599 | 0.000 | 6.601 | 0.000 |
| No | | 695 (93.0) | 216 (83.7) | (1.683 – 4.012) | | (2.935 – 14.847) | |



| | | | | | | | | |
|---|--|------------|-------------|--------------------------|-------|-----------------|-------|--|
| Diseases of the genitourinary system | | | | | | | | |
| Yes | | 42 (5.6) | 19 (7.4) | 1.334 | 0.314 | - | - | |
| No | | 705 (94.4) | 239 (92.6) | (0.761 – 2.339) | | - | - | |
| Injury, poisoning and certain other consequences of external causes | | | | | | | | |
| Yes | | 29 (3.9) | 8 (3.1) | 0.792 | 0.566 | - | - | |
| No | | 718 (96.1) | 250 (96.9) | (0.357 – 1.756) | | - | - | |
| Certain infectious and parasitic diseases | | | | | | | | |
| Yes | | 21 (2.8) | 11 (4.3) | 1.540 | 0.255 | - | - | |
| No | | 726 (97.2) | 247 (95.7) | (0.732 – 3.239) | | - | - | |
| Diseases of musculoskeletal system and connective tissue | | | | | | | | |
| Yes | | 22 (2.9) | 1 (0.4) | 0.128 | 0.045 | 1.974 | 0.582 | |
| No | | 725 (97.1) | 257 (99.6) | (0.017 – 0.956) | | 0.175 – 22.209 | | |
| Diseases of the skin and subcutaneous tissue | | | | | | | | |
| Yes | | 10 (1.3) | 3 (1.2) | 0.867 | 0.829 | - | - | |
| No | | 737 (98.7) | 255 (98.8) | (0.237 – 3.175) | | - | - | |
| Neoplasms | | | | | | | | |
| Yes | | 6 (99.2) | 4 (98.4) | 1.945 | 0.306 | - | - | |
| No | | 741 (0.8) | 254 (1.6) | (0.544 – 6.947) | | - | - | |
| Diseases of the blood and blood-forming organs | | | | | | | | |
| Yes | | 4 (0.5) | 1 (0.4) | 0.723 | 0.772 | - | - | |
| No | | 743 (99.5) | 257 (99.6) | (0.080 – 6.496) | | - | - | |
| Disorders of gallbladder, biliary tract and pancreas | | | | | | | | |
| Yes | | 3 (0.4) | 0 (0.0) | 0.000 | 0.999 | - | - | |
| No | | 774 (99.6) | 258 (100.0) | (0.000 –) | | - | - | |
| Charlson Comorbidity Index | | | | | | | | |
| No comorbidity (0) | | 325 (79.1) | 86 (20.9) | - | - | - | - | |
| Mild (1 – 2) | | 402 (71.9) | 157 (28.1) | 0.132 (0.012 – 1.476) | 0.100 | - | - | |
| Moderate (3 – 4) | | 19 (59.4) | 13 (40.6) | 0.195 (0.018 – 2.169) | 0.184 | - | - | |
| Severe (≥ 5) | | 1 (33.3) | 2 (66.7) | 0.342 (0.028 – 4.176) | 0.401 | - | - | |
| Number of prescribed medications | | | | | | | | |
| <5 | | 680 (95.5) | 32 (4.5) | 4.011 | - | 4.373 | - | |
| ≥ 5 (polypharmacy) | | 67 (22.9) | 226 (77.1) | (3.345 – 4.809) | 0.000 | (3.540 – 5.401) | 0.000 | |
| <i>MRCI</i> medication regimen complexity index | | | | | | | | |

This study also found that polypharmacy had a strong correlation with the MRCI value. This is in line with previous studies, which denoted that the number of medications and changes in the dosing frequency associated with the MRCI value ($p < 0.001$).⁴³ Additionally, Advinha et al. described that MRCI value would increase by increasing therapy⁴⁵ and greater MRCI scores are predictive of readmission to hospital.⁴⁷

This study has several limitations. First, we did not assess all drugs listed on the 2019 AGS Beers Criteria® available due to hospital formulary at the research site and this single-center study limits the generalizability of the findings beyond the

catchment area served by the study center. Nevertheless, our relatively large number of visits increases the power of the study and limits the possibility of type 1 error.

Moreover, to our knowledge, this study is the first to be conducted in Indonesia to assess the prevalence and risk factors for PIM (using the 2019 AGS Beers Criteria®) and medication complexity (using MRCI) among older adults. In addition, the study was conducted in the ED, which has a specificity of the intervention in services. Therefore, our findings will serve as a benchmark for future studies exploring other determinants of PIM use and the medication regimen complexity in Indonesia.



There are no studies that state the cut-off value of MRCI, which can be a reference for categorizing high treatment complexity. Based on the data we collected, it is suggested that future research is needed with varied backgrounds (country, service setting, disease, and number of drugs) and need for some validation and reliability study on the MRCI to be able to determine a universally acceptable cut-off value to define medication complexity are high, moderate or low. Hopefully, after knowing the complexity threshold, PIM and high medication complexity can be controlled to improve patient safety and develop health intervention strategies.

CONCLUSION

Our study found that more than half of older adults admitted

to the ED had PIMs, and a high medication complexity was observed. Patients with disease of Endocrine, nutritional and metabolic disease was risk factors for both PIMs and medication regimen complexity. A strict monitoring and vigilance are needed on PIMs and medication regimen complexity in the elderly with disease groups mentioned in this research to prevent the potential adverse impacts on vulnerable patients and improve the health system.

ACKNOWLEDGEMENT

The authors would like to express our gratitude to Arina Dery Puspitasari and Ahmad Dzulfikri Nurhan for their support on this project.

References

1. Zhang X, Zhou S, Pan K, et al. Potentially Inappropriate Medications in Hospitalized Older Patients: A Cross-sectional Study Using The Beers 2015 Criteria versus the 2012 criteria. *Clin Interv Aging*. 2017;12:1697-1703. <https://doi.org/10.2147/CIA.S146009>
2. Curtin D, Gallagher P F, O'Mahony D. Explicit criteria as clinical tools to minimize inappropriate medication use and its consequences. *Ther Adv Drug Saf*. 2019;10:1-10. <https://doi.org/10.1177/2042098619829431>
3. Thorell K, Midlöv P, Fastbom J, et al. Importance of potentially inappropriate medications, number of chronic conditions and medications for the Risk of hospitalisation in elderly in Sweden: a case-control study. *BMJ Open*. 2019;9(9):1-9. <https://doi.org/10.1136/bmjopen-2019-029477>
4. 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. *J Am Geriatr Soc*. 2019;67(4):674-694. <https://doi.org/10.1111/jgs.15767>
5. Chang WT, Kowalski SR, Sorich W, et al. Medication regimen complexity and prevalence of potentially inappropriate medicines in older patients after Hospitalisation. *Int J Clin Pharm*. 2017;39(4):867-873. <https://doi.org/10.1007/s11096-017-0490-y>
6. Khamis S, Abdi AM, Uzan A, Basgut B. Applying Beers Criteria for elderly patients to assess rational drug use at a university hospital in Northern Cyprus. *J Pharm Bioallied Sci*. 2019;11(2):133. https://doi.org/10.4103/jpbs.JPBS_208_18
7. Klotz U. Pharmacokinetics and drug metabolism in the elderly. *Drug Metab Rev*. 2009;41(2):67-76. <https://doi.org/10.1080/03602530902722679>
8. Legramante JM, Morciano L, Lucaroni F, et al. Frequent use of emergency departments by the elderly population when continuing care is not well established. *PLoS One*. 2016;11(12):e0165939. <https://doi.org/10.1371/journal.pone.0165939>
9. Hall MJ, Rui P, Schwartzman A. Emergency Department Visits by Patients Aged 45 and over with Diabetes. 2018.
10. Rizka A, Harimurti K, Pitoyo CW, et al. Performa rapid emergency medicine score (REMS) dalam memprediksi mortalitas 30 hari pasien usia lanjut di instalasi gawat darurat. *J. Penyakit Dalam Indones*. 2017;4(2):62-67. <http://dx.doi.org/10.7454/jpdi.v4i2.116>
11. Farmer M. Strategies aimed at improving medication safety, transitions of care, health information technology, and other factors in the ED can significantly decrease the risks of adverse events. *Emerg. Med*. 2016;(48):397-404.
12. Chang CB, Lai HY, Hwang SJ, et al. Prescription of potentially inappropriate medication to older patients presenting to the emergency department: a nationally representative population study. *Sci Rep*. 2018;8(1):1-8. <https://doi.org/10.1038/s41598-018-30184-4>
13. Reis CM, dos Santos AG, de Jesus Souza P, et al. Factors associated with the use of potentially inappropriate medications by older adults with cancer. *J Geriatr Oncol*. 2017;8(4):303-307. <https://doi.org/10.1016/j.jgo.2017.05.003>
14. George J, Phun YT, Bailey MJ, et al. Development and validation of the medication regimen complexity index. *Ann Pharmacother*. 2004;38:1369-1376. <https://doi.org/10.1345/aph.1D479>
15. Wimmer BC, Johnell K, Fastbom J, et al. Factors associated with medication regimen complexity in older people: a cross-sectional population-based study. *Eur J Clin Pharmacol*. 2015;71(9):1099-1108. <https://doi.org/10.1007/s00228-015-1883-2>
16. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40(5):373-383. [https://doi.org/10.1016/0021-9681\(87\)90171-8](https://doi.org/10.1016/0021-9681(87)90171-8)
17. Blanco-Reina E, Valdellós J, Aguilar-Cano L, et al. 2015 Beers Criteria and STOPP v2 for detecting potentially inappropriate medication in community-dwelling older people: prevalence, profile, and risk factors. *Eur J Clin Pharmacol*. 2019;75(10):1459-



1466. <https://doi.org/10.1007/s00228-019-02722-0>
18. Federman AD, O'conor R, Wolf MS, et al. Associations of Medication Regimen Complexity with COPD Medication Adherence and Control. *Int J Chron Obstruct Pulmon Dis*. 2021;16:2385. <https://doi.org/10.2147/COPD.S310630>
 19. Farmer BM, Hayes BD, Rao R, et al. The role of clinical pharmacists in the emergency department. *J. Med. Toxicol*. 2018;14(1):114-116. <https://doi.org/10.1007/s13181-017-0634-4>
 20. WHO. International Statistical Classification of Diseases and Related Health Problems 10th Revision. 2019.
 21. Simões PA, Santiago LM, Maurício K, et al. Prevalence of potentially inappropriate medication in the older adult population within primary care in Portugal: a nationwide cross-sectional study. *Patient Prefer Adherence*. 2019;13:1569-1576. <https://doi.org/10.2147/PPA.S219346>
 22. Sharma R, Bansal P, Garg R, et al. Prevalence of potentially inappropriate medication and its correlates in elderly hospitalized patients: A cross-sectional study based on Beers criteria. *J Fam Community Med*. 2020;27(3):200-207. https://doi.org/10.4103/jfcm.JFCM_175_20
 23. Price SD, Holman CDAJ, Sanfilippo FM, et al. Association between potentially inappropriate medications from the Beers criteria and the risk of unplanned hospitalization in elderly patients. *Annals of Pharmacotherapy*. 2014;48(1):6-16. <https://doi.org/10.1177/1060028013504904>
 24. Xing XX, Zhu C, Liang HY, et al. Associations between potentially inappropriate medications and adverse health outcomes in the elderly: a systematic review and meta-analysis. *Annals of Pharmacotherapy*. 2019;53(10):1005-1019. <https://doi.org/10.1177/1060028019853069>
 25. Al-Azayzih A, Alamoori R, Altawalbeh SM. Potentially inappropriate medications prescribing according to beers criteria among elderly outpatients in Jordan: A cross sectional study. *Pharm Pract (Granada)*. 2019;17(2):1-7. <https://dx.doi.org/10.18549/pharmpract.2019.2.1439>
 26. Khader H, Hasoun LZ, Alsayed A, et al. Potentially inappropriate medications use and its associated factors among geriatric patients: a cross-sectional study based on 2019 Beers Criteria. *Pharmacia*. 2021;68(4):789-795. <https://doi.org/10.3897/pharmacia.68.e73597>
 27. Najjar MF, Sulaiman SAS, Al Jeraisy M, et al. The impact of a combined intervention program: An educational and clinical pharmacist's intervention to improve prescribing pattern in hospitalized geriatric patients at King Abdulaziz Medical City in Riyadh, Saudi Arabia. *Ther Clin Risk Manag*. 2018;14:557-564. <https://doi.org/10.2147/TCRM.S157469>
 28. Komagamine J. Prevalence of potentially inappropriate medications at admission and discharge among hospitalised elderly patients with acute medical illness at a single centre in Japan: A retrospective cross-sectional study. *BMJ Open*. 2018;8(7):1-8.
 29. Abraham DS, Nguyen TP, Hennessy S, et al. Frequency of and risk factors for potentially inappropriate medication use in parkinson's disease. *Age Ageing*. 2020;49(5):786-792. <https://doi.org/10.1093/ageing/afaa033>
 30. Abdelwahed AA, El-Dahiyat F, Aljawamis D, et al. Potentially inappropriate medications in older adults according to Beers criteria 2019: Prevalence and risk factors. *Int J Clin. Pract*. 2021;75(11):1-8. <https://doi.org/10.1111/ijcp.14715>
 31. Tian F, Li H, Chen Z, et al. Potentially inappropriate medications in Chinese older outpatients in tertiary hospitals according to Beers criteria: A cross-sectional study. *Int J Clin Pract*. 2021;75(8):1-9. <https://doi.org/10.1111/ijcp.14348>
 32. Al-Dahshan A, Kehyayan V. Prevalence and predictors of potentially inappropriate medication prescription among older adults: a cross-sectional study in the State of Qatar. *Drugs - Real World Outcomes*. 2021;8(1):95-103. <https://doi.org/10.1007/s40801-020-00220-9>
 33. Jo YY, Kim YB, Yang MR, Chang YC. Extrapyramidal side effects after metoclopramide administration in a post-anesthesia care unit - A case report -. *Korean J Anesthesiol*. 2012;63(3):274-276. <https://doi.org/10.4097/kjae.2012.63.3.274>
 34. Gorzoni ML, Rosa RF. Beers AGS 2019 criteria in very old hospitalized patients. *Rev Assoc Med Bras*. 2020;66(7):918-923. <https://doi.org/10.1590/1806-9282.66.7.918>
 35. Jeon HL, Park J, Han E, et al. Potentially inappropriate medication and hospitalization/emergency department visits among the elderly in Korea. *Int J Qual Heal Care*. 2018;30(1):50-56. <https://doi.org/10.1093/intqhc/mzx171>
 36. DePestel DD, Aronoff DM. Epidemiology of Clostridium difficile infection. *J Pharm Pract*. 2013;26(5):464-475. <https://doi.org/10.1177/0897190013499521>
 37. Maes ML, Fixen DR, Linnebur SA. Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence. *Ther Adv Drug Saf*. 2017;8(9):273-297. <https://doi.org/10.1177/2042098617715381>
 38. Saqlain M, Ali H, Kamran S, Munir MU, Jahan S, Mazhar F. Potentially inappropriate medications use and its association with health-related quality of life among elderly cardiac patients. *Qual Life Res*. 2020;29(10):2715-2724. <https://doi.org/10.1007/s11136-020-02530-5>
 39. Abegaz TM, Birru EM, Mekonnen GB. Potentially inappropriate prescribing in Ethiopian geriatric patients hospitalized with cardiovascular disorders using START/STOPP criteria. *PLoS One*. 2018;13(5):1-14. <https://doi.org/10.1371/journal.pone.0195949>
 40. Sheikh-Taha M, Dimassi H. Potentially inappropriate home medications among older patients with cardiovascular disease admitted to a cardiology service in USA. *BMC Cardiovasc Disord*. 2017;17(1):1-6. <https://doi.org/10.1186/s12872-017-0623-1>
 41. T. Alhawassi, W. Alatawi, and M. Alwhaibi. Prevalence of potentially inappropriate medications use among older adults and



- risk factors using the 2015 American Geriatrics Society Beers Criteria. *BMC Geriatr.* 2019;19(1):1-8.. <https://doi.org/10.1186/s12877-019-1168-1>
42. Temrel T, Şahin S. Polypharmacy and potentially inappropriate medication use in geriatric patients presenting to the emergency department. *Turk Geriatr Derg.* 2019;22(1):25-31.
 43. Thorell K, Midlöv P, Fastbom J, Halling A. Use of potentially inappropriate medication and polypharmacy in older adults: a repeated cross-sectional study. *BMC Geriatr.* 2020;20(1):73. <https://doi.org/10.1186/s12877-020-1476-5>
 44. Pantuzza LLN, das Graças Braga Ceccato M, Reis EA, Silveira MR, Almeida-Brasil CC, Almeida TA, Pinto IVL, Reis AMM. Factors associated with high medication regimen complexity in primary care older adults in Brazil. *Eur Geriatr Med.* 2020;11(2):279-287. <https://doi.org/10.1007/s41999-019-00275-0>
 45. Parveen, N, Afzal M, Hussain M, Gilani SA. Knowledge regarding Safe Administration of Parenteral Medication among Nurses. *Eur Acad Res.* 2019;7(1).
 46. Advinha AM, De Oliveira-Martins S, Mateus V, et al. Medication regimen complexity in institutionalized elderly people in an aging society. *Int J Clin Pharm.* 2014;36(4):750-756. <https://doi.org/10.1007/s11096-014-9963-4>
 47. Wilson MN, Greer CL, Weeks DL. Medication regimen complexity and hospital readmission for an adverse drug event. *Annals of Pharmacotherapy.* 2013;48(1):26-32. <https://doi.org/10.1177/1060028013510898>



Lampiran 1



**KOMITE ETIK PENELITIAN
RUMAH SAKIT UNIVERSITAS AIRLANGGA**

KETERANGAN LOLOS KAJI ETIK
No : 177/KEP/2020

Komite Etik Penelitian Rumah Sakit Universitas Airlangga dalam upaya melindungi hak asasi dan kesejahteraan subyek penelitian, telah mengkaji dengan teliti protokol penelitian yang berjudul:


Analisis Potentially Inappropriate Medications (PIMs) dan Kompleksitas Regimen Terapi pada Pasien Lanjut Usia

Peneliti : **Khusnul Fitri Hamidah**

Institusi Penelitian : Rumah Sakit Universitas Airlangga

DINYATAKAN LAIK ETIK.

Surabaya, 16 September 2020



Prof. Dr. Muhammad Amin, dr., Sp.P (K)
NIDK 8804680018

- ❖ Keterangan Lolos Kaji Etik berlaku 1 (satu) tahun sejak tanggal penetapan
- ❖ Jika dalam kurun waktu 1 (satu) tahun penelitian masih belum selesai, maka penelitian akan dihentikan dan peneliti diwajibkan melakukan perpanjangan Keterangan Lolos Kaji Etik

Teste de Inglês Científico

Pharmacy Practice

COUNTRY

Spain

 Universities and research institutions in Spain

 Media Ranking in Spain

SUBJECT AREA AND CATEGORY

Health Professions
Pharmacy

Pharmacology, Toxicology and
Pharmaceutics
Pharmaceutical Science

PUBLISHER

Centro de Investigaciones y
Publicaciones Farmaceuticas

H-INDEX

28

PUBLICATION TYPE

Journals

ISSN

1885642X, 18863655

COVERAGE

2006-2021

INFORMATION

[Homepage](#)

[How to publish in this journal](#)

journal@pharmacypractice.org



CPHI
China

PMEC
China


Meet at the
2nd largest
pharma
market

[REGISTER NOW](#)

19-21 June 2023 | Shanghai, China

SCOPE

Pharmacy Practice is a free full-text peer-reviewed journal with a scope on pharmacy practice. Pharmacy Practice is published quarterly. Pharmacy Practice does not charge and will never charge any publication fee or article processing charge (APC) to the authors. The current and future absence of any article processing charges (APCs) is signed in the MoU with the Center for Pharmacy Practice Innovation (CPPPI) at Virginia Commonwealth University (VCU) School of Pharmacy. Pharmacy Practice is the consequence of the efforts of a number of colleagues from different Universities who believe in collaborative publishing: no one pays, no one receives. Although focusing on the practice of pharmacy, Pharmacy Practice covers a wide range of pharmacy activities, among them and not being comprehensive, clinical pharmacy, pharmaceutical care, social pharmacy, pharmacy education, process and outcome research, health promotion and education, health informatics, pharmacoepidemiology, etc.

 Join the conversation about this journal

Submit paper for publication


Submit paper for publication

FIND SIMILAR JOURNALS

options

| | | | | |
|---|---|---|---|--|
| 1 International Journal of Pharmacy Practice GBR 73% similarity | 2 Research in Social and Administrative Pharmacy USA 72% similarity | 3 International Journal of Clinical Pharmacy NLD 59% similarity | 4 Journal of Pharmaceutical Health Services Research GBR 58% similarity | 5 Journal of Pharmacy Practice and Research USA 49% similarity |
|---|---|---|---|--|

Submit paper for publication



Pharmacy Practice

Q2 Pharmaceutical Science
best quartile

SJR 2021
0.41

powered by scimagojr.com

Show this widget in your own website

Just copy the code below and paste within your html code:

``



Explore, visually communicate and make sense of data with our **new data visualization tool.**

